FTC Wants More Info On Sanofi-Aventis Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
"Second request" is “standard practice when investigating a friendly transaction of this significance," Sanofi says. Deal is still on schedule for second quarter close.
You may also be interested in...
Sanofi-Aventis Picks Two To Head U.S.: Rothwell, Soriot On Management Committee
Sanofi's Tim Rothwell will continue to serve as U.S. CEO, while Aventis' Soriot will head U.S. commercial operations. French market regulator extends closing date of merger to July 30, citing extra time needed for FTC review.
Sanofi-Aventis Picks Two To Head U.S.: Rothwell, Soriot On Management Committee
Sanofi's Tim Rothwell will continue to serve as U.S. CEO, while Aventis' Soriot will head U.S. commercial operations. French market regulator extends closing date of merger to July 30, citing extra time needed for FTC review.
Sanofi Extends Aventis Offer To June 30
The extension would just meet Sanofi’s goal to close the Aventis merger in the second quarter. The European Commission approved sale of Arixtra and Fraxiparine to GlaxoSmithKline May 26; FTC decision on merger is pending.